Formulation: A solid
Formal Name: L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysine, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C119H212N46O26 • XCF3COOH
Formula Weight: 2703,3
Shelf life (days): 1460
Notes: Tat-Gap 19 is a peptide inhibitor of connexin43 (Cx43) hemichannels.{59785} It is composed of the HIV-1 Tat protein transduction domain linked to a nine-amino acid peptide corresponding to residues 128-136 of Cx43. Tat-Gap 19 (10 µM) inhibits glutamate-induced ATP release, a marker of Cx43 hemichannel activity, in primary rat hepatocytes.{65897} It reduces infarct volume in a mouse model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 25 mg/kg.{59785} Intraperitoneal infusion of Tat-Gap 19 (1 mg/kg per day) reduces fibrotic lesion area and the area of hepatic stellate cells, precursors of myofibroblasts, expressing α-smooth muscle actin (α-SMA) in a mouse model of thioacetamide-induced liver injury.{65897} It increases superoxide dismutase (SOD) activity in hepatic cells isolated from the same mice.
English
Deutsch
